ArticleMolecular cancer therapeutics2013

Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma.

H Eirik Haarberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.